当前位置: X-MOL 学术Neuro Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
Neuro-Oncology ( IF 15.9 ) Pub Date : 2020-07-01 , DOI: 10.1093/neuonc/noaa115
Martin van den Bent , Marica Eoli , Juan Manuel Sepulveda , Marion Smits , Annemiek Walenkamp , Jean-Sebastian Frenel , Enrico Franceschi , Paul M Clement , Olivier Chinot , Filip de Vos , Nicolas Whenham , Paul Sanghera , Michael Weller , H J Dubbink , Pim French , Jim Looman , Jyotirmoy Dey , Scott Krause , Pete Ansell , Sarah Nuyens , Maarten Spruyt , Joana Brilhante , Corneel Coens , Thierry Gorlia , Vassilis Golfinopoulos

Corrigendum to Bent et al. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro Oncol (doi: 10.1093/neuonc/noz222) first published online November 20, 2019.

中文翻译:

INTELLANCE 2/EORTC 1410 随机 II 期研究更正 Depatux-M 单独和与替莫唑胺对比替莫唑胺或洛莫司汀治疗复发性 EGFR 扩增胶质母细胞瘤

Bent 等人的更正。INTELLANCE 2/EORTC 1410 在复发性 EGFR 扩增型胶质母细胞瘤中单独使用 Depatux-M 和与替莫唑胺对比替莫唑胺或洛莫司汀的随机 II 期研究。Neuro Oncol (doi: 10.1093/neuonc/noz222) 于 2019 年 11 月 20 日首次在线发布。
更新日期:2020-07-01
down
wechat
bug